EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC)

This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3 chronic hepatitis C (CHC) infection.

Study Overview

• Status: Completed
• Conditions: Hepatitis C
• Intervention / Treatment: Drug: EDP-494; Drug: Placebo

Detailed Description

The first phase explores single ascending doses of EDP-494 (active drug or placebo) in healthy subjects. A 'fasted' vs 'fed' two-part cohort will also assess food effect.

The second phase involves multiple ascending doses (active drug or placebo) for 14 days in healthy subjects.

The third, proof of concept, phase will assess two different doses for 14 days each in Hepatitis C patients.

Each cohort within each phase will consist of 8 subjects randomized to either EDP-494 or placebo in a 3 to 1 ratio, with the exception of the food effect cohort, which will consist of 10 subjects randomised in a 4 to 1 ratio.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 1

Contacts and Locations

Study Locations

• New Zealand
  • Auckland, New Zealand, 1150
    • Auckland Clinical Studies Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria for Healthy Volunteers (SAD and MAD Phases):

• Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.
• Female subjects must be of non-childbearing potential.
• All male participants who have not had a vasectomy must use effective contraception from Day -1 to 90 days after their last dose of study drug.
• Body mass index of 18 to 30 kg/m2 with a minimum body weight of 50 kg.
• An informed consent document signed and dated by the subject.

Exclusion Criteria for Healthy Volunteers (SAD and MAD Phases):

• Clinically relevant evidence or history of illness or disease
• Pregnant or nursing females.
• History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
• A positive urine drug screen at screening or Day -1.
• Any condition possibly affecting drug absorption (e.g., gastrectomy).
• History of regular alcohol consumption
• Participation in a clinical trial within 30 days prior to study drug administration.
• Use of prescription drugs, non-prescription drugs, dietary supplements, herbal supplements, hormonal therapy/replacement or CYP3A4 substrates, inducers and inhibitors within 14 days prior to the first dose of study medication

Inclusion Criteria for HCV-Infected Subjects (POC Phase):

• Males and females aged 18 years and less than 70 years.
• Female subjects must be of non-childbearing potential.
• All male participants who have not had a vasectomy must use effective contraception from Day -1 to 90 days after their last dose of study drug.
• Body mass index of 18 to 36 kg/m2 with a minimum body weight of 50 kg.
• Treatment naïve subjects with chronic HCV infection,
• HCV GT1 (including 1a, 1b, or mixed subtypes of GT1) or GT3.
• HCV RNA ≥100,000 IU/mL at screening.
• An informed consent document signed and dated by the subject.

Exclusion Criteria for HCV-Infected Subjects (POC Phase):

• Women of childbearing potential (WOCBP).
• Pregnant or nursing females.
• History of febrile illness within 7 days prior to the first dose of study drug.
• A positive urine drug screen at screening unless on an approved prescription.
• History of participation in a clinical trial with a polymerase inhibitor or previous treatment with a polymerase inhibitor, where at least one dose of the polymerase inhibitor was consumed. Subjects who were dosed with placebo on a clinical trial may be enrolled in this study.
• Clinically significant electrocardiogram abnormalities or QTcF greater than 450 msec for males and 470 msec for females at either screening or baseline, or any prior history of QT abnormality.
• Co-infection with HIV-1, HIV-2 or HBV.

• Have clinically significant laboratory abnormalities at screening:

  • Absolute neutrophil count (ANC) < 1500/mm2 (1.5 x 109L)
  • Platelets <90,000/mm2 (90 x 109L)
  • Hemoglobin < 13g/dL for males and < 12g/dL for females
  • Serum creatinine >1.5 x upper limit of normal (ULN) or creatinine clearance < 50 mL/min; estimated by the cockcroft -Gault formula [(140-age) x weight (kg)/72 x serum creatinine (mg/dL), if female multiply by 0.85]
  • Total bilirubin greater than the ULN
  • Serum alanine transaminase (ALT) > 5 x ULN
  • Serum aspartate aminotransferase (AST) > 5 x ULN
  • Alkaline phosphatase > 1.25 x ULN
  • Pancreatic Amylase > 1.1 x ULN
  • Alpha fetoprotein (AFP) > 50 ng/mL unless a liver imaging study (CT, MRI) shows no clinically significant lesions within 6 months prior to the first dose of study drug.
• Patients with evidence of cirrhosis; cirrhosis is defined as any one of the following: a) any biopsy showing cirrhosis (Knodell score <3, Metavir score <3, Ishak score <4); b) Fibroscan evaluation within 6 months prior to screening with a liver stiffness score of ><12.5 kPa.
• Other significant, unstable or uncontrolled medical history, such as neurological, endocrine, malignancy, renal, psychiatric, respiratory, cardiac, gastrointestinal, allergic, immunological, etc. disease.
• Use of concomitant medications, including vitamins or herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EDP-494 SAD Cohorts; EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration	Drug: EDP-494; 10, 100 and 200 mg capsules
Experimental: EDP-494 MAD/POC Cohorts; EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days	Drug: EDP-494; 10, 100 and 200 mg capsules
Placebo Comparator: EDP-494 SAD Placebo Cohort	Drug: Placebo; placebo to match EDP-494
Placebo Comparator: EDP-494 MAD/POC Placebo Cohort	Drug: Placebo; placebo to match EDP-494

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, and abnormal clinical laboratory results administered to healthy volunteers and multiple doses of EDP-494	Tabulation of the number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, echo and abnormal clinical laboratory results (including chemistry, hematology, and urine). Administered to healthy volunteers and multiple doses of EDP-494 administered to healthy volunteers and subjects with Chronic Hepatitis C (CHC) genotype 1 and 3 infection	From screening and baseline to the 4 week follow-up visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	EDP-494 and metabolites	0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72 (Day 4), 96 (Day 5), 120 (Day 6)*, 144 (Day 7) and 168 (Day 8) hrs postdose
Cmax	EDP-494 and metabolites	Day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 5, 7, 9, 12: 0 (Predose); Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120, 144 and 168 hrs postdose
AUC	EDP-494 and metabolites	0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120*, 144, and 168 hrs postdose
AUC	EDP-494 and metabolites	Day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 5, 7, 9, 12: 0 (Predose);Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120, 144 and 168 hrs postdose
Change from baseline in plasma HCV RNA (log10 IU/mL)		Baseline up to 14 days
Amino Acid Changes in HCV polymerase NS5b		Baseline up to 3 months

Collaborators and Investigators

• Sponsor: Enanta Pharmaceuticals, Inc
• Collaborators: Novotech (Australia) Pty Limited
• Investigators: Principal Investigator: Edward Gane, MD, Auckland Clinical Studies (ACS),

Study record dates

Study Major Dates

• Study Start (Actual): January 10, 2016
• Primary Completion (Actual): December 27, 2016
• Study Completion (Actual): December 27, 2016

Study Registration Dates

• First Submitted: January 6, 2016
• First Submitted That Met QC Criteria: January 7, 2016
• First Posted (Estimate): January 11, 2016

Study Record Updates

• Last Update Posted (Estimate): January 23, 2017
• Last Update Submitted That Met QC Criteria: January 20, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis; Hepatitis A; Hepatitis C
• Other Study ID Numbers: EDP-494-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Once the clinical study report has been submitted to the appropriate Regulatory authorities, a lay person summary will be provided to all study subjects by mail or email.